Literature DB >> 16022019

Admission preoperative glucose is predictive of morbidity and mortality in trauma patients who require immediate operative intervention.

Grant V Bochicchio1, Laura Salzano, Manjari Joshi, Kelly Bochicchio, Thomas M Scalea.   

Abstract

Although there have been reports in the surgical literature regarding the negative effects of preoperative hyperglycemia on outcome, the impact of elevated preoperative serum glucose levels in trauma patients is unknown. Our objectives were to determine whether preoperative hyperglycemia was associated with a greater morbidity and mortality in trauma patients who underwent surgical intervention upon admission. Prospective data was collected on 252 consecutive nondiabetic trauma patients admitted for > or =3 days who went directly to the OR from the resuscitation area. Patients were stratified by preoperative serum glucose level (<200 vs. > or =200 mg/dL) age, gender, Injury Severity Score (ISS), and other preexisting risk factors. Outcome was measured by incidence of infection, hospital (HLOS) and ICU (ILOS) length of stay, and mortality. Multiple linear regression models were used to evaluate serum glucose in relation to other preoperative risk factors. Blunt trauma accounted for the majority (86%) of the injuries. Orthopedic procedures were the most common (36%) followed by neurosurgical (22%), abdominal (22%), and thoracic (6%). Patients with elevated serum glucose had a significantly greater incidence of infection, HLOS, ILOS, and mortality matched per age and ISS. Elevated serum glucose on admission is an accurate predictor of postoperative infection, HLOS, ILOS, and mortality. A randomized prospective trial evaluating the impact of preoperative glucose control is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16022019

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  24 in total

1.  Finding the sweet spot: identification of optimal glucose levels in critically injured patients.

Authors:  Matthew E Kutcher; Marci B Pepper; Diane Morabito; Dharma Sunjaya; M Margaret Knudson; Mitchell Jay Cohen
Journal:  J Trauma       Date:  2011-11

2.  Dynamic electrochemistry: a step in the right direction.

Authors:  Mark J Rice
Journal:  J Diabetes Sci Technol       Date:  2011-09-01

3.  Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.

Authors:  Chau-Chyun Sheu; Michelle N Gong; Rihong Zhai; Feng Chen; Ednan K Bajwa; Peter F Clardy; Diana C Gallagher; B Taylor Thompson; David C Christiani
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

4.  Statistical and clinical analysis of alterations in glucose values after burns.

Authors:  M K Belba; E Petrela; A Belba; V Mano; G Belba
Journal:  Ann Burns Fire Disasters       Date:  2016-09-30

5.  Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals.

Authors: 
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

6.  Diabetes does not influence selected clinical outcomes in critically ill burn patients.

Authors:  Chaitanya K Dahagam; Alejandra Mora; Steven E Wolf; Charles E Wade
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

Review 7.  Blood glucose control in the trauma patient.

Authors:  James Eakins
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

Review 8.  Glucose control and its implications for the general surgeon.

Authors:  Maya Leggett; Brian G Harbrecht
Journal:  Am Surg       Date:  2009-11       Impact factor: 0.688

9.  [Glucose control in the critically ill. Innovations and contemporary strategies].

Authors:  U Holzinger
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-05-19       Impact factor: 0.840

10.  Visceral adiposity is not associated with inflammatory markers in trauma patients.

Authors:  Bryan Collier; Lesly Dossett; Jason Shipman; Matthew Day; George Lawson; Robert Sawyer; Addison May
Journal:  J Trauma       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.